COMMUNIQUÉS West-GlobeNewswire

Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements
04/06/2025
Shipments include initial deliveries of SecureGard™ and SoloGard™ smart safety syringes from its Hungary-based manufacturing facility Deliveries mark the Company’s transition to a commercial-stage, revenue-generating [...]
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
04/06/2025
Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from [...]
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
04/06/2025
Gold-level Stevie® Award recognizes Maetzold’s transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle [...]
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
04/06/2025
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46 th Annual Global Healthcare Conference on Wednesday, [...]
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
04/06/2025
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to [...]
Revive Therapeutics Advances with Next-Generation Bucillamine Development
04/06/2025
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative [...]
Accumulus Synergy and Veeva Systems Partner to Advance Regulatory Transformation and Connectivity
04/06/2025
BURLINGAME, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Today, Accumulus Synergy (“Accumulus”) announced a strategic partnership with Veeva Systems (“Veeva”) focused on enabling connectivity to help the life sciences [...]
Accumulus Synergy et Veeva Systems s’associent afin d’accélérer la transformation réglementaire et la connectivité
04/06/2025
BURLINGAME, Calif., 04 juin 2025 (GLOBE NEWSWIRE) -- Accumulus Synergy (« Accumulus ») a annoncé aujourd’hui un partenariat stratégique avec Veeva Systems (« Veeva ») axé sur la mise en place de solutions de [...]
TOLREMO therapeutics Announces TT125-802 is the First CBP/p300 Bromodomain Inhibitor to Show Clinical Activity in Solid Tumors
04/06/2025
- Deep and durable responses in drug-resistant KRAS-G12C- and EGFR-mutant NSCLC - Best-in-class safety profile highlights potential for development in combination to treat patients with KRAS-G12C-mutant NSCLC, EGFR- [...]
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
04/06/2025
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet [...]
Molecular Health and Axxam enter into a strategic partnership to bolster the discovery of innovative targets in drug development
04/06/2025
Pairing data-driven clinical-molecular insights with biological validation to identify relevant drug targets and confirm leads for biopharmaceutical companies MILAN, Italy and HEIDELBERG, Germany, June 04, 2025 (GLOBE [...]
Philips to repurchase up to 6 million shares to cover long-term incentive plans
04/06/2025
June 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive [...]
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
04/06/2025
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology Ignites strong momentum in immunology & inflammation pipeline through lusvertikimab development, [...]
OSE Immunotherapeutics renforce sa stratégie de croissance : Accélération des programmes clés dans l'inflammation et de l'immuno-oncologie
04/06/2025
OSE Immunotherapeutics renforce sa stratégie de croissance : Accélération des programmes clés dans l'inflammation et de l'immuno-oncologie Insuffler un nouvel élan en immunologie et inflammation grâce au développement [...]
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
04/06/2025
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in [...]
Ose Immunotherapeutics : Documents made available to the shareholders for the combined general meeting of June 25th, 2025
04/06/2025
Documents made available to the shareholders for the combined general meeting of June 25 th , 2025 Nantes, June 4 th , 2025, 8 a.m. - OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnemo: OSE) announces the publication [...]
Ose Immunotherapeutics : Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 25 juin 2025
04/06/2025
Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 25 juin 2025 Nantes, le 4 juin 2025, 8 heures – OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnémo: OSE) annonce la mise en ligne des [...]
Ex dividend NOK 1.25 today
04/06/2025
The shares in Vistin Pharma ASA (VISTN) will be traded ex dividend NOK 1.25 as from today, 04.06.2025.
Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
04/06/2025
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers the same efficacy and safety demonstrated in available oral solution [...]

Pages